|
Bagadilico, ''Basal Ganglia Disorders Linnaeus Consortium'', is a research group in Lund, Sweden, and a Linnaeus environment, supported by the Swedish Research Council. The group consists of about 120 researchers at either Lund University or Lund University Hospital. The group’s ultimate goal is to find new therapies for Parkinson's disease and Huntington's disease. These disorders have in common that they are caused by disturbances in the part of the brain called the basal ganglia. To achieve this goal, the group wants to establish and develop a strong, multidisciplinary research environment. The ambition with the programme is to receive knowledge that improves the patients’ quality of life, through improved therapies and methods of diagnosis, and also improves the situation for the families. Researchers from Lund University Medical Faculty, Faculty of Engineering, Cultural Sciences and Lund University Hospital make up the group. The aim of this collaboration is for new therapies to be made available to the patients more quickly, and that ethical and cultural aspects are taken into consideration. The medical part of the research focuses on cell transplantation, gene therapy and finding new drugs. New clinical trials where dopamine-producing cells will be transplanted into the brains of patients with Parkinson's disease are planned for 2010. An important part of the programme is acquiring knowledge of how therapies best are designed to benefit patients, their families and the society as a whole, and to take into consideration the ethical and cultural aspects of progress in biomedical research. The name Bagadilico is an acronym formed using the two initial letters from the words Basal Ganglia Disorders Linnaeus Consortium. == Related Research Environments == MultiPark () cell-CARE () AXREGEN () 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Bagadilico」の詳細全文を読む スポンサード リンク
|